Pansito, Emelyn C.
HRN: 22-80-73 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/26/2023
CO-AMOXICLAV 625MG (TAB)
04/26/2023
05/03/2023
PO
625mg
BID X 7days
S/P NSVD With 2nd Degree RMLE And Repair
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes